Bladé J, Carreras E, Rozman C, Sierra J, Rovira M, Batlle M, Valls A, Algara M, Marín P, Urbano-Ispizua A
Escuela de Hematología Farreras-Valentí, Departamento de Medicina, Hospital Clínic i Provincial, Universidad de Barcelona.
Med Clin (Barc). 1995 Jun 3;105(1):1-4.
Allogeneic bone marrow transplantation (BMT) is the only potentially curative treatment in multiple myeloma (MM).
From january 1986 to december 1993, 12 cases (10 males and 2 females) underwent BMT in the authors' institution. The mean age of the series was 39 years (range 23-49). The situation of the myeloma on initiation of the conditioning was: complete remission (CR) in 2 cases, objective response in 5 cases, partial response in 1 case and treatment resistance in 4 cases. The conditioning schedule included cyclophosphamide (120 mg/kg) and total body irradiation (10-14 Gy) with or without melfalan at high doses in 11 patients and busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in 1 case. The prophylaxis of graft versus host disease (GVHD) was carried out with methotrexate and cyclosporine A (CsA) in 7 cases, CsA plus prednisone in 2 cases and 3 patients received CsA plus bone marrow partially depleted of T lymphocytes by elutriation.
The situation of the myeloma with regard to response following transplantation was: unevaluable in 1 case, resistant in 1 case, objective response in 2 cases and CR in 8 cases. Seven out of the 10 patients at risk presented grades II-IV GVHD. Four of the 8 patients who were in CR following transplantation died due to post transplant complications and 2 out of the 6 relapsed 9 months after the transplant while 2 remain in CR at 5 and 8 years after the transplant, respectively. Nine patients died due to infection in 2 cases, GVHD and infection in 4 cases, GVHD and hemorrhage in 1 case and progression and infection in 2 cases. Of the 3 surviving patients, 1 relapsed at 14 months after the transplant and two remain in CR at 5 and 8 years post transplantation.
Bone marrow transplantation conditioning gives place to a high number of complete remission in multiple myeloma. However, the incidence of acute grade II-IV graft versus host disease and mortality due to complications related to the transplantation are very high. Nonetheless, a proportion of patients may achieve curation with bone marrow transplantation.
异基因骨髓移植(BMT)是多发性骨髓瘤(MM)唯一具有潜在治愈可能的治疗方法。
1986年1月至1993年12月,作者所在机构有12例患者(10例男性,2例女性)接受了BMT。该组患者的平均年龄为39岁(范围23 - 49岁)。开始预处理时骨髓瘤的情况为:2例完全缓解(CR),5例客观缓解,1例部分缓解,4例治疗抵抗。预处理方案包括11例患者使用环磷酰胺(120mg/kg)和全身照射(10 - 14Gy),加或不加高剂量马法兰,1例患者使用白消安(16mg/kg)和环磷酰胺(120mg/kg)。7例患者采用甲氨蝶呤和环孢素A(CsA)预防移植物抗宿主病(GVHD),2例患者采用CsA加泼尼松,3例患者接受CsA加通过淘洗部分去除T淋巴细胞的骨髓。
移植后骨髓瘤的反应情况为:1例不可评估,1例抵抗,2例客观缓解,8例CR。10例有风险的患者中有7例出现II - IV级GVHD。移植后处于CR的8例患者中有4例因移植后并发症死亡,6例中有2例在移植后9个月复发,2例分别在移植后5年和8年仍处于CR状态。9例患者死亡,2例死于感染,4例死于GVHD和感染,1例死于GVHD和出血,2例死于病情进展和感染。3例存活患者中,1例在移植后14个月复发,2例分别在移植后5年和8年仍处于CR状态。
骨髓移植预处理使多发性骨髓瘤患者大量达到完全缓解。然而,急性II - IV级移植物抗宿主病的发生率以及与移植相关并发症导致的死亡率非常高。尽管如此,一部分患者可能通过骨髓移植实现治愈。